The biochemical definition of subclinical hypothyroidism (SH) is an elevation of serum thyroid stimulating hormone (TSH) or thyrotropin level with the associated triioditroponin (T3) and thyroxine (T4) levels in normal reference range. If not prevented at the initial phase, SH eventually progresses into overt hypothyroidism thereby taking a massive toll on the human health. With the advancement of alternative science over the recent decades, a novel pain-free approach has been discussed that successfully treats SH within a span of two months. In this case study, a 23-year old woman reports severe fatigue, mild mood swings and constipation. Physical examination denotes no enlargement of the thyroid gland. However, laboratory results reports an elevated serum TSH of 9.85 µIU/mL (reference range: 0.39-6.16 µIU/mL) with normal free T3 (1.79 ng/ml, reference range: 0.52-1.85 ng/ml) and T4 (10.17 µIU/mL, reference range: 4.6-11.2 µIU/mL) levels. To prevent the progression of the condition, “Neurotherapy” treatment is provided to the patient. This study aimed to assess the efficacy of this novel treatment in a patient with SH. Post the therapy, laboratory results show a significant reduction of the serum thyroid stimulating hormone with no associated side-effects, thereby confirming the effectiveness of neurotherapy treatment for the prevention and further progression of this condition.

Subclinical hypothyroidism

overt hypothyroidism

thyroid stimulating hormone

neurotherapy

View PDF View HTML View XML